65th ASH Annual Meeting & Exposition: 703. Cellular Immunotherapies: Basic and Translational: Evaluating Strategies to Enhance Cellular Immunotherapies

Symposia: Cellular Immunotherapies: Basic and Translational Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, AML, Biological therapies, Translational Research, Lymphomas, non-Hodgkin lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, immunology, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes

Room 6B (San Diego Convention Center)

Moderators:

Saad S. Kenderian, MD, Mayo Clinic and Rebecca M Richards, MD, PhD,

Disclosures:

Kenderian: Novartis: Consultancy, Honoraria, Patents & Royalties, Research Funding, Speakers Bureau; Kite/Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Juno/BMS: Other: Membership on an entity's board of directors or advisory committees, Research Funding; Humanigen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding, Speakers Bureau; MustangBio: Patents & Royalties; Sendero: Patents & Royalties; Mettaforge: Patents & Royalties; Lentigen: Research Funding; Tolero/Sumtomo: Research Funding; Morphosys: Research Funding; LEAHLabs: Consultancy, Current equity holder in private company, Research Funding; CapstanBio: Consultancy, Other: Scientific advisory board; Torque: Consultancy; Luminary therapeutics: Other: scientific advisory board .

4:30 PM

1015

High Levels of Circulating Granulocytic Myeloid-Derived Suppressor Cells (G-MDSCs) Predict Failure of CD19-Targeting CAR-T Cell Therapy

Eugenio Galli¹^*, Alessandra Battaglia²^*, Marco Fossati³^*, Ilaria Pansini⁴^*, Silvia Bellesi⁵^*, Alexia Buzzonetti³^*, Nicole Zampetti³^*, Stefan Hohaus^4,5^*, Andrea Bacigalupo, MD⁵, Patrizia Chiusolo^4,5^*, Simona Sica^4,5^*, Andrea Fattorossi³^* and Federica Sorà, MD^4,5^*

¹Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
²Dipartimento di Scienze della vita e sanità pubblica, Università Cattolica del Sacro Cuore, Rome, Italy
³Cytometry Facility, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
⁴Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy
⁵Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

4:45 PM

1016

Low Dose Total Body Irradiation Improves CD19 CAR-T Expansion, Persistence, and Trafficking, Leading to Enhanced Efficacy in Large B-Cell Lymphoma

Mohammad Alhomoud, MD¹, Michelle Foley, MD^1,2^*, Mayumi Sugita, MD¹^*, Takahiro Yamazaki³^*, Leandro Martinez¹^*, Samuel Yamshon, MD¹^*, Alexandra Gomez-Arteaga, MD¹^*, Paul Pagnini³^*, Tsiporah B. Shore, MD¹, Olivier Boyer, MD, PhD⁴, Renier Brentjens, MD PhD⁵, Koen Van Besien, MD, PhD¹, Lorenzo Galluzzi³^*, Silvia Formenti³^*, Jeremie Martinet⁴^* and Monica L. Guzman, PhD⁶

¹Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY
²Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Radiation Oncology, Weill Cornell Medical College, New York, NY
⁴Department of Immunology and Biotherapy, Rouen University Hospital, Rouen, France
⁵Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
⁶Division of Hematology and Oncology, Weill Cornell Medical College Division of Hematology/Oncology, New York, NY

5:00 PM

1017

Bone Marrow Stroma Impairs CAR-T Cell Proliferation and Function: Mechanistic Insights

Francesco Dazzi¹^*, Roberto Savoldelli, BSc²^*, Alice Pievani, PhD³^*, Sarah Tettamanti, PhD⁴^*, Chiara Giacomini, PhD²^*, Anna Kozlowska, PhD⁵^* and Marta Serafini, PhD⁶^*

¹AstraZeneca Biopharma R&D, Cambridge, United Kingdom
²King's College London, London, United Kingdom
³Centro Ricerca M. Tettamanti, Department of Pediatrics, University of Milan Bicocca, Monza, ITA
⁴University of Milan Bicocca, Monza, Monza-Brianza, ITA
⁵Biopharma Cell Therapy R&D, AstraZeneca, Gothenburg, Sweden
⁶Centro Tettamanti, University of Milan Bicocca, MONZA, AL, ITA

5:15 PM

1018

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

Patrizia Porazzi, PhD¹^*, Yusuke Isshiki, MD, PhD², Guido Ghilardi, MD³^*, Siena Nason³^*, Ziqi Yang³^*, Alberto Carturan, MD³^*, Linhui Chen³^*, Yunlin Zhang, MS¹^*, Ruchi P. Patel, MS³, Puneeth Guruprasad⁴^*, Ositadimma Ugwuanyi, BS³^*, Ivan J Cohen, PhD³^*, Stephen J Schuster, MD^3,5, Ari M Melnick, MD², Wendy Beguelin, PhD⁶^* and Marco Ruella, MD^3,5,7

¹Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
²Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY
³Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
⁴Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, North Wales, PA
⁵Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁶Department of Medicine, Weill Cornell Medical College, New York, NY
⁷Lymphoma Program, University of Pennsylvania, Philadelphia, PA

5:30 PM

1019

TP53 Deficiency in AML Confers Resistance to CAR T-Cells That Can be Overcome By Targeting the Cholesterol or Wnt Pathways

Jan Mueller, MD PhD¹^*, Roman Schimmer, MD¹^*, Christian Koch, MD²^*, Florin Schneiter, MSc³^*, Jonas Fullin, MSc¹^*, Veronika Lysenko, PhD¹^*, Renier Myburgh, PhD²^*, Laura Volta¹^*, Alexandre Theocharides, MD¹^*, Kari Kurppa, PhD⁴^*, Benjamin L. Ebert, MD, PhD⁵, Timm Schroeder⁶^*, Markus G. Manz, MD⁷ and Steffen Boettcher, MD⁸^*

¹University Hospital Zurich, Zurich, Switzerland
²University and University Hospital Zurich, Zurich, Switzerland
³ETH Zurich, Basel, Switzerland
⁴University of Turku and Åbo Akademi University, Turku, FIN
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Department of Biosystems Sciences and Engineering, ETH Zurich, Basel, Switzerland
⁷Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
⁸University Hospital Zurich, Zurich, Zurich, Switzerland

5:45 PM

1020

Precision Targeting of the Malignant Clone in Diffuse Large B Cell Lymphoma Using Chimeric Antigen Receptor T Cells Against the Clonotypic IGHV4-34 B Cell Receptor

Ivan J Cohen¹^*, Audrey C Bochi-Layec¹^*, Ki Hyun Kim, PhD¹^*, Scott Jenks, PhD²^*, Ositadimma Ugwuanyi, BS³^*, Guido Ghilardi, MD³^*, Giulia Gabrielli, MD¹^*, Jaryse Harris, MD⁴^*, Li-Ping Wang⁴^*, Yunlin Zhang, MS¹^*, Raymone Pajarillo, MS¹^*, Elisavet Vlachonikola⁵^*, Patrizia Porazzi, PhD¹^*, Ignacio Sanz, MD²^*, Paolo Ghia, MD, PhD⁶, Kostas Stamatopoulos⁵, Stephen J Schuster, MD⁷^* and Marco Ruella, MD^3,7,8,9

¹Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA
²Lowance Center for Human Immunology, Emory University, Atlanta, GA
³Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
⁴Department of Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA
⁵Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
⁶Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
⁷Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁸Department of Medicine, Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
⁹Lymphoma Program, University of Pennsylvania, Philadelphia, PA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.O1.6 703. Cellular Immunotherapies: Basic and Translational: Evaluating Strategies to Enhance Cellular Immunotherapies